Clinical trials: Prostate Cancer, Castration Resistant
Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
COMbination of Bipolar Androgen Therapy and Nivolumab
Single arm, multicenter, open-label Phase II study of the effects of parenteral testosterone in combination with nivolumab in men with metastatic castration-resistant prostate cancer who previously progressed on at least one…
- Conditions
- Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
- Trial name
- COMBAT-CRPC (NCT03554317)
- Testing
- Testosterone cypionate, Nivolumab
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Neoplasms
A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
The purpose of this study is to evaluate the safety and efficacy of abiraterone acetate when co-administered with prednisone in Asian patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed…
- Trial name
- NCT01695135
- Testing
- Abiraterone acetate, Prednisone
- Where
- 11 sites in China
- Volunteers
- 214 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Castration-resistant Prostate Cancer
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Trial name
- NCT04556617
- Testing
- PLX2853 20 mg, Olaparib, Abiraterone acetate
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 19 people
- Sponsor
- Opna Bio LLC
Prostate Cancer
Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
The purpose of this study is to determine if continued treatment with Enzalutamide is effective in patients with metastatic prostate cancer.
- Trial name
- PLATO (NCT01995513)
- Testing
- Enzalutamide, Abiraterone, Prednisone
- Where
- 95 sites in United States, Australia and 9 more
- Volunteers
- 509 people
- Sponsor
- Pfizer
Prostate Cancer Metastatic
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Docetaxel and cabazitaxel are cancer chemotherapy agents of the taxane drug class. The purpose of this study is to explore the benefit, for treatment of metastatic castration-resistant prostate cancer (mCRPC), of a regimen in…
- Trial name
- TAXYNERGY (NCT01718353)
- Testing
- DOCETAXEL (XRP6976), CABAZITAXEL (XRP6258), Prednisone
- Where
- 19 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Sanofi
Prostate Cancer
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to find out whether the new drug PX-866 will slow the growth of your prostate cancer. The investigators will also watch you carefully for any side effects that PX-866 might cause.
- Trial name
- NCT01331083
- Testing
- PX-866
- Where
- 10 sites in Canada
- Volunteers
- 68 people
- Sponsor
- NCIC Clinical Trials Group
Prostate Cancer
GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer
The purpose of this study is to assess the effect of GTx-758 on Serum Prostate-specific antigen (PSA) levels in men with castrate resistant prostate cancer who are maintained on androgen deprivation therapy (Serum PSA response…
- Trial name
- NCT01420861
- Testing
- GTx-758
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- GTx
Prostate Cancer
A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)
The purpose of this study is to evaluate the effectiveness, safety and tolerability of nivolumab followed by ipilimumab, in subjects with metastatic castration resistant prostate cancer (mCRPC).
- Trial name
- CheckMate 650 (NCT02985957)
- Testing
- Nivolumab, Ipilimumab, Cabazitaxel
- Where
- 59 sites in United States, Australia and 8 more
- Volunteers
- 351 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer
CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
This protocol is designed to provide participants currently benefiting from rucaparib treatment in a Clovis-sponsored clinical study with continued access to treatment for as long as they continue to benefit.
- Conditions
- Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- CATCH-R (NCT04676334)
- Testing
- Rucaparib
- Where
- 25 sites in Canada, Israel and 4 more
- Volunteers
- 34 people
- Sponsor
- pharmaand GmbH
Prostate Cancer
Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer
Background: Enzalutamide is a hormone therapy that is used to treat advanced prostate cancer. It is given after chemotherapy and surgery to help the body destroy the cancer cells.
- Trial name
- NCT01867333
- Testing
- PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -F/TRICOM, PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -V/TRICOM, Enzalutamide
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Castration-Resistant Prostate Carcinoma, Recurrent Prostate Carcinoma
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
This randomized phase II trial studies abiraterone acetate and prednisone together with veliparib to see how well it works compared to abiraterone acetate and prednisone alone in treating patients with castration-resistant…
- Conditions
- Castration-Resistant Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
- Trial name
- NCT01576172
- Testing
- Abiraterone Acetate, Laboratory Biomarker Analysis, Prednisone
- Where
- 14 sites in United States
- Volunteers
- 159 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy
This study will investigate the safety and efficacy of Sacituzumab Govitecan in patients with metastatic castration-resistant prostate cancer progressing on second generation androgen receptor (AR) directed therapy (e.g.…
- Trial name
- NCT03725761
- Testing
- Sacituzumab Govitecan
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- University of Wisconsin, Madison
Prostate Carcinoma Metastatic to the Bone, Castration Resistant Prostate Cancer
A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)
The purpose of this study is to evaluate 18F-sodium fluoride positron-emission tomography / computed tomography (18F-NaF PET/CT) imaging as a method for determining treatment response in metastatic bone lesions in patients who…
- Trial name
- NCT02384382
- Testing
- Enzalutamide
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Pfizer
Prostate Cancer
A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer
The purpose of this study is to assess the safety and efficacy in Korea or Taiwan of oral abiraterone acetate and oral prednisolone in men with metastatic-castration resistant prostate cancer (mCRPC) and with disease progression…
- Trial name
- NCT01685983
- Testing
- Abiraterone acetate, Prednisolone
- Where
- 8 sites in South Korea, Taiwan
- Volunteers
- 82 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer
Background: Prostate cancer is the most common cancer type among men. Some prostate cancers respond to hormonal therapy. However, some cell characteristics of other prostate cancers cause it not to respond as well to these…
- Trial name
- NCT01867424
- Testing
- Eovist
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Prostatic Neoplasms, Castration-Resistant
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to: a) establish the recommended phase 2 dose (RP2D) and to evaluate the antitumor activity and safety of niraparib combination therapies (Combinations 1 and 2) and b) to determine the relative…
- Trial name
- QUEST (NCT03431350)
- Testing
- Niraparib 200 mg, Cetrelimab 240 mg, Cetrelimab 480 mg
- Where
- 50 sites in United States, Belgium and 5 more
- Volunteers
- 136 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Study of Immunotherapy to Treat Advanced Prostate Cancer
The purpose of the study is to determine if advanced prostate cancer patients that are treated with radiotherapy (RT) plus ipilimumab live longer that those treated with RT alone
- Trial name
- NCT00861614
- Testing
- Ipilimumab
- Where
- 158 sites in United States, Argentina and 25 more
- Volunteers
- 988 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer
This is a global, multi-center, open-label, randomized phase 1b/2, active-controlled safety and efficacy study of oral administration of tazemetostat in combination with enzalutamide or abiraterone/prednisone (phase 1b) versus…
- Trial name
- CELLO-1 (NCT04179864)
- Testing
- Tazemetostat, Abiraterone/prednisone, Enzalutamide
- Where
- 24 sites in United States, Belgium and 1 more
- Volunteers
- 102 people
- Sponsor
- Epizyme, Inc.
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer
This phase II trial studies how well testosterone (enanthate or cypionate) and olaparib work in treating patients with prostate cancer that has progressed despite hormonal therapy.
- Trial name
- NCT03516812
- Testing
- Laboratory Biomarker Analysis, Olaparib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Washington
Metastatic Castration Resistant Prostate Cancer, Prostate Neoplasms
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
Background: Some prostate cancer keeps growing even when testosterone in the body drops to very low levels. This is called castrate-resistant prostate cancer. One treatment is enzalutamide. This is a modern hormonal therapy.
- Trial name
- NCT03531827
- Testing
- enzalutamide, CRLX101
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)